This article is more than 5 years old. Information may no longer be current.

Illumina partners with Watson for Genomics to assist with data interpretation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IBM Watson Health and Illumina today announced their partnership to integrate Watson for Genomics into Illumina’s BaseSpace and Tumor Sequencing Process, according to a press release.

The collaboration will incorporate Watson for Genomics (IBM Watson Health) into next-generation sequencing platform data produced by TruSight Tumor 170 (Illumina) — a solid tumor profiling panel designed to detect a comprehensive set of variants across 170 genes.

Watson for Genomics will read the genetic alteration files produced by TruSight Tumor 170 and produce a report for researchers based on a search on the genetic alterations in professional guidelines, medical literature, clinical trials and other sources. Watson for Genomics adds new information on approximately 10,000 scientific articles and 100 new clinical trials every month.

“To enable precision cancer medicine on a large scale, we need new tools to overcome the data barriers of genomic research,” John Leite, PhD, vice president of oncology at Illumina, said in the release. “With a comprehensive assay of Illumina and the power of Watson, we hope to deliver a rapid turnaround of the genomic alteration results.”

The Watson for Genomics software will be available to support Illumina’s TruSight Tumor 170 assay early this year, the release said.

“This partnership lays the groundwork for more systematic study of the impact of genomics in oncology,” Deborah DiSanzo, general manager of IBM Watson Health, said in the release. “Together we are poised to help researchers realize the potential of precision oncology by expanding access to valuable genome sequencing from Illumina and reliable, standardized genomic interpretation from Watson.”